Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
PHASE 1/2A OPEN-LABEL CLINICAL TRIAL EVALUATING VBC101, AN EGFR AND CMET TARGETED BI-SPECIFIC ANTIBODY DRUG CONJUGATE, IN PARTICIPANTS WITH ADVANCED SOLID TUMOR MALIGNANCIES
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed …
Participants With Advanced Solid Tumor Malignancies
Estimated
~$10 – $8,750
VelaVigo Bio IncNCT07136779
Phase 1
Phase 1/2a Open-Label Clinical Trial Evaluating VBC106, an FRα- and MSLN-Directed Bispecific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential b…
Participants With Advanced Solid Tumor Malignancies
Estimated
~$10 – $8,750
VelaVigo Bio IncNCT07686068